Comparative Pharmacology
Head-to-head clinical analysis: CYTOSAR U versus REDITREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOSAR U versus REDITREX.
CYTOSAR-U vs REDITREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cytarabine is an antimetabolite that inhibits DNA synthesis by competing with cytidine for incorporation into DNA, causing chain termination and inhibiting DNA polymerase.
REDITREX is a folate analog metabolic inhibitor that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for purine and pyrimidine synthesis. This leads to inhibition of DNA synthesis and cell proliferation.
Cytarabine 100-200 mg/m² IV continuous infusion over 24 hours for 5-7 days (induction) or 1-3 g/m² IV every 12 hours for 6 doses (high-dose cytarabine).
15 mg/m2 intramuscularly or intravenously once weekly; maximum single dose 30 mg.
None Documented
None Documented
The terminal elimination half-life of cytarabine is 1-3 hours for the initial phase (alpha) and 2-6 hours for the terminal phase (beta), with a mean of approximately 2.5 hours. In patients with renal impairment, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal elimination half-life is 3-10 hours in patients with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Cytosar-U (cytarabine) is primarily excreted renally as inactive metabolite uracil arabinoside (Ara-U). Approximately 70-80% of a dose is recovered in urine within 24-48 hours, with <10% excreted as unchanged drug. Biliary/fecal elimination is minimal (<5%).
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; minimal biliary/fecal elimination (<10%).
Category C
Category C
Antineoplastic Antimetabolite
Antineoplastic Antimetabolite